Kornimate/medical-research-clean huggingface dataset:
decreasing the stigma of mental illness among health science students through a mentoring program

Conditions: Social Stigma

Summary: stigma towards people with mental health problems is a serious public health problem that limits access to treatment and social participation, in addition to being considered the main barrier to inclusion and quality of health care. this stigma also affects students and health professionals, impacting the quality of care and help seeking in mental health. in this context, it is necessary to develop innovative and effective interventions among university students to reduce this stigma and promote an inclusive and recovery-based approach. the aim of the present research project is to analyze the effect of a mentoring program on levels of stigma and mental health help-seeking intention in psychology and nursing students. this three-session mentoring program is based on experiential learning and has been validated and adapted to our country. the mentors, professionals with lived experience in mental health, will provide knowledge and experiences to the students through direct contact sessions in the classroom, focusing especially on the processes of recovery and self-determination. research question: what is the effect of a mentoring program on levels of stigma and mental health help-seeking intention in health care students? within the dependent variables of the study are the measurement of levels of stigma and mental health help-seeking intention in students. the independent variables will be the type of group (experimental and control), age, gender and career. methodology: quantitative study, including the participation of health students in the experimental and control groups. the sample size was determined using the g\*power software. after approval by the institutional ethics committee and signature of the informed consent of the participants, the mentoring program will be implemented in the classroom. for this purpose, the levels of stigma and intention to seek mental health help in both groups will be measured using nationally and internationally validated instruments, before, after and at 4 weeks. data analysis will be performed using a mixed anova model to compare pre- and post-intervention outcomes between the two groups. the present study will provide valuable evidence on the effectiveness of mentoring-based interventions in reducing stigma in health care students, a key group in the future provision of care for people with mental health problems. the results will also lay the groundwork for larger-scale studies to assess the impact of the intervention in other groups and settings, with the potential to significantly improve the quality of care and well-being of patients and their families.


Eligibility criteria:
inclusion criteria: * university students from health careers * sign the informed consent form. exclusion criteria: * be under 18 years of age.
coronary anomalies in congenital heart disease

Conditions: Congenital Heart Disease

Summary: this is a retrospective study. the investigators shall review the angiography data of 1200 consecutive cardiac catheterizations of children and babies with chd (congenital heart disease) since 1998 till now. coronary artery origin and course will be evaluated in relation to the morphologic cardiac anomalies. coronary artery anomalies will be described and statistical analysis will be performed.


Eligibility criteria:
inclusion criteria: * cradiac catheterization with angiography with congenital heart disease. exclusion criteria: * no congenital heart disease.

Keywords: chd
pk of meropenem in patients on plasma exchange

Conditions: Autoimmune Diseases

Summary: therapeutic plasma exchange (tpe) has been shown to be an important procedure for treatment of a variety of refractory immune complex disorders, such as guillain-barré syndrome and neuromyelitis optica. the intervention removes plasma, albumin, or some other substance. meropenem is a broad-spectrum beta-lactam antimicrobial agent that is used for the treatment of serious nosocomial infections. pathophysiological changes in patients on tpe can alter the pharmacokinetic (pk) patterns of coadministered antibiotics. this effect has an impact on the antimicrobial agents when paticipants are administered during the intervention. the aim of this study was to investigate the impact of tpe on meropenem pk.


Eligibility criteria:
inclusion criteria: * age≥ 18 years * no shock * hemoglobin ≥ 7 g/dl exclusion criteria: * pregnancy or breast-feeding female * history of hypersensitivity to carbapenems * renal replacement therapy

Keywords: therapeutic plasma exchange meropenem pharmacokinetic
incidence of venous thromboembolism and professional practices in brest area

Conditions: Venous Thromboembolism

Summary: the aim of this study estimate vte incidence. investigators prospectively record all cases of symptomatic pulmonary embolism (pe) and deep vein thrombosis (dvt) of the lower limbs diagnosed between march 1, 2013 and february 28, 2014 in hospitals and in the community.


Eligibility criteria:
inclusion criteria: * symptomatic pulmonary embolism (pe) and deep vein thrombosis (dvt) diagnosis confirmed * patient living in brest area from time of diagnosis exclusion criteria: * invalid diagnosis * asymptomatic event * main residence patient out of brest area.

Keywords: venous thromboembolism professional practices
evaluation of the effect of fluoride and laser application on the prevention of sensitivity in bleached teeth

Conditions: Dentin Sensitivity

Summary: to investigate the effects of desensitizing agents on the dental bleaching process, testing the hypothesis that they may prevent dental sensitivity.

the objective of this double blind, randomized and controlled clinical study, was to evaluate the efficacy of 1.1% sodium fluoride associated with lllt (low level laser therapy) on teeth that were exposed to 35% hydrogen peroxide during 4 weeks of bleaching treatment. methods: 25 volunteers were evaluated through the split-mouth model, where the hemiarcates were ranzomized and later allocated in one of the experimental groups: g-fluor+laser - constitutes the group treated with lllt + 1.1% sodium fluoride; and g-fluor - constitutes the group treated with placebo + 1.1% sodium fluoride .

Eligibility criteria:
inclusion criteria: * absence of active carious lesions; * good oral hygiene; * do not present hypersensitivity; * do not smoke; * not being pregnant. exclusion criteria: * presence of periodontal disease; * presence of cracks or fractures; * presence of restorations and prostheses; * presence of gastroesophageal dysfunction; * patients with severe internal dental dimming.
sfib vs anterior qlb in total hip arthroplasty

Conditions: Pain

Summary: quadratus lumborum block (qlb) is a facial plane block defined to provide analgesia from t7-l3 dermatomes. there are articles reporting that it is an effective analgesic method in hip surgeries. suprainguinal fascia iliaca block (sifib) also blocks components of the lumbar plexus and provides effective analgesia in hip surgeries. the investigators aim to compare the effectiveness of qlb and sifib in patients undergoing primary total hip arthroplasty (tha).


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) classification i-ii-iii * scheduled for total hip artroplasty surgery under spinal anesthesia exclusion criteria: * patients who did not want to participate in the study * patients with cognitive dysfunction who cannot evaluate the nrs score and cannot use pca * known local anesthetics and opioid allergy, * pregnancy or lactation * patients with a contraindication to spinal and regional anesthesia * presence of multiple fractures

Keywords: postoperative pain management total hip arthroplasty suprainguinal fascia iliaca block anterior qlb
a study of ixekizumab in participants with plaque psoriasis

Conditions: Psoriasis

Summary: this study is known as a "drug interaction study." the purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam) that are metabolized by cytochrome p450. each participant will complete two study periods. participants will take the mixture of commonly used drugs (plus vitamin k) by mouth on 3 occasions (prior to treatment with ixekizumab and after 1 and 12 weeks of treatment with ixekizumab). the study will last about 17 weeks, including follow-up. screening must be completed prior to study start.


Eligibility criteria:
inclusion criteria: * males and females with chronic moderate or severe plaque psoriasis for at least 6 months who are candidates for systemic therapy or phototherapy * men and women of childbearing potential must agree to use a reliable method of birth control and men may not donate sperm for the duration of the study. women must test negative for pregnancy at screening and agree not to become pregnant during the study and until the first normal period following the end of the study * have a body mass index (bmi) of 18.5 to 40.0 kilograms per square meter (kg/m²), inclusive, at screening * have greater than or equal to (≥) 10 percent body surface area (bsa) involvement at screening and first admission to the clinical research unit (cru) * have both a static physicians global assessment (spga) score of ≥3 and psoriasis area severity index (pasi) score ≥12 at screening and first admission to the cru exclusion criteria: * forms of psoriasis other than chronic plaque-type * pregnant or nursing (lactating women) * history of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection * have major surgery within 8 weeks prior to first admission to the clinical research unit or during the study * have a history of lymphoproliferative disease, or signs or symptoms of lymphoproliferative disease, or have active or history of malignant disease, or have uncontrolled cerebrocardiovascular or neuropsychiatric disease * require treatment with the cocktail drugs or with inhibitors of cytochrome p450 (cyp) 3a, cyp2c9, cyp2d6, cyp2c19, cyp1a2, or with inducers of cyp3a or cyp1a2, or with rifampin (inducer of multiple cyps) or with substrates of cyp3a, cyp2c9, cyp2d6, cyp2c19, or cyp1a2 with narrow therapeutic indices within 14 days prior to the first administration of the drug cocktail through the end of week 12 assessments * have any known allergy or hypersensitivity to any component of the study cocktail or ixekizumab * have participated in any other study with ixekizumab, secukinumab or brodalumab, or have been prescribed ixekizumab or secukinumab
a basket trial of vunakizumab in inflammatory skin diseases

Conditions: Inflammatory Skin Diseases; Psoriasis

Summary: this is a national multi-center, large sample size case registration clinical study. the registry population was patients with inflammatory skin diseases who were receiving treatment with vunakizumab. all outpatient and inpatient patients with inflammatory skin diseases who were receiving vunakizumab were eligible for enrollment. patients' usual care was not affected by participation in the study. we only collected data in routine clinical practice. the study had an enrollment period of 5 years or 10,000 patients were recruited early, whichever occurred first. all patients must provide written informed consent form before data collection, and each patient will be followed for 1 year to observe clinical progression.


Eligibility criteria:
inclusion criteria: * aged ≥ years； * had adiagnosis of inflammatory skin disease； * is receiving or plans to receive vunakizumab for treatment; * patients provided written informed consent form. exclusion criteria: * no.

Keywords: inflammatory skin diseases psoriasis vunakizumab
socioeconomic aspects before and after radiation therapy in patient with prostate cancer

Conditions: Prostate Cancer

Summary: this trial is an interrogation of patients with prostate cancer to evaluate socioeconomic effects of radiotherapy. patients with percutaneous or interstitial or combined percutaneous and interstitial radiotherapy are included. beside medical effects and adverse events, it's prospectively needed to extensively inform patients about socioeconomic aspects associated with radiotherapy. the interrogation comprises to collect possible costs and expenditures during and after therapy. aspects especially concerning post therapy period include additional consultations, individual applied alternative medical care, need for additional medical aids (salves, medicine, bandages) and changes in professional and social situation. it's figured out in what extend costs are absorbed by health insurance coverage. in germany there is no appropriate trial with respective patient population and respective therapy. primary endpoint is the evaluation of therapy concerning and follow-up costs as well as changes in social and professional situation. secondary endpoints are quality of life, adverse events of therapy and the correlation of quality of life, adverse events and economic aspects for the patient and the health insurance coverage.


Eligibility criteria:
inclusion criteria: * minimal age 18 * low, mediate and high-grade prostate cancer exclusion criteria: * tumor recurrence * surgery as primary therapy * prior radiotherapy except conventional radiotherapy * patients with other malignancies

Keywords: socioeconomic aspects costs of therapy follow-up costs primary radiation percutaneous interstitial
a new fast dwi-based mr protocol for surveillance in patients with a high risk of ovarian cancer recurrence during parp-inhibitors maintenance to enhance secondary cytoreduction results

Conditions: Ovarian Cancer; Recurrent Ovarian Carcinoma

Summary: in ovarian cancer (oc), complete surgical debulking and platinum-based chemotherapy are the standard treatment, now followed by maintenance therapy with parp inhibitors or bevacizumab. however, in advanced-stage ovarian cancer, recurrence is common, with a progression-free survival of about 16 months. secondary cytoreductive surgery (scs) at the time of recurrence prolongs the overall survival and gives the possibility to extend the use of parp-i. scs is possible only when recurrence has limited extension. however, in oc, there is no well-established and widely accepted scheme for surveillance during maintenance therapy; esmo guidelines suggest physical examination for the follow-up and allow ultrasound, ct, pet-ct and mri to confirm the recurrence and plan surgical treatment if appropriate.

patients with oc in surveillance after first-line treatment usually have a scheme of clinical visits and serum marker evaluation every three months, associated with alternated transvaginal ultrasound and chest, abdomen and pelvis ct with contrast every three months and mri with a confirmatory role in some cases. we will use an abbreviated mr protocol of the abdomen (the most common location of relapse and the only one that can be treated by surgery) in association with ct. the abbreviated protocol is based on axial b50, b600 and b900 dwi with three-dimensional coronal maximum intensity projection (mip) reconstruction of b900 values, adc maps and axial single-shot t2-weighted sequences, which will take less than 20 minutes. this mri protocol does not need contrast injection and does not add any risk for patients. any positive findings will be discussed at the multidisciplinary tumour board and secondary cytoreductive surgery will be evaluated. surgery outcome and subsequent clinical information (secondary pfs and os) derived by normal clinical practise will be registered in a dedicated database.

Eligibility criteria:
inclusion criteria: * patients with brca wild-type, hrp, high-grade serous ovarian cancer * no residual tumour at first debulking surgery * more than 6 months since the last platinum-based therapy exclusion criteria: * patients who will not consent to participate in the study
prevalence of vertebral fractures in hiv infected patients older than 50 years

Conditions: Vertebral Fractures

Summary: prospective cohort study to determine the prevalence of vertebral fractures in hiv infected patients older than 50 years.

to determine the prevalence of asymptomatic vertebral fractures in hiv patients older than 50 years, and the risk of fracture during a follow up of 2 years, according to bone mineral density at inclusion, the level of serum bone biomarkers, and the presence of secondary factors such as hypovitaminosis d or/and secondary hyperparathyroidism.

Eligibility criteria:
inclusion criteria: * age above 50 years * hiv infection exclusion criteria: * pregnancy * receiving corticosteroids or antiresorptive therapy

Keywords: hiv bone fractures vitamin d biomarkers
feasibility and usability of a pedometer in a cardiovascular disease prevention program for french-speaking canadians

Conditions: Cardiovascular Disease

Summary: the purpose of this prospective randomized controlled trial (rct) is to evaluate the feasibility and usability of a commercial pedometer and web application in a case-managed home-based cardiovascular disease prevention and rehabilitation program for french-speaking canadians.

a cardiovascular disease (cvd) prevention and rehabilitation program is an evidence-based, standard of care for those who have coronary artery disease or other cardiac conditions; the aim of cvd prevention and rehabilitation program is to minimize disease progression and prevent future cardiovascular events. behaviour change interventions targeting exercise are effective for improving physical activity levels, but can be intensive and costly. activity monitors with accompanying web applications may provide a practical compliment to behaviour change interventions as an affordable way to promote and sustain increased physical activity levels, as measured by steps and physical activity levels. to date, no studies have examined the role of a pedometer with accompanying web application on steps and physical activity levels in french-speaking canadians attending the francoforme® cardiac prevention and rehabilitation program at the university of ottawa heart institute. it is also unknown the average daily steps of canadian francophone patients. identifying successful interventions that promote physical activity among cvd prevention and rehabilitation program patients will help to improve their health as well as decrease the risk of first or subsequent cardiovascular events.

Eligibility criteria:
inclusion criteria: * francophone (i.e., french-speaking); * ≥18 years; * existing atherosclerotic vascular disease or ≥1 risk factor for cvd (e.g., family history of premature cvd, age \[sex dependent\], smoking, sedentary lifestyle, diabetes, hypertension, hypercholesterolemia, overweight/obesity); * live in the champlain region and attending the onsite francoforme® intake; * have a family physician or nurse practitioner (to order blood tests and titrate medications); * patient agrees to sign informed consent. exclusion criteria: * unwilling to wear activity monitors; * unable to engage in physical activity; * does not have access to the internet; * unable to attend follow-up visits; * unable to provide written, informed consent.

Keywords: pedometer usability usability and feasibility web application
effects of oxytocin on reinforcement learning

Conditions: Learning Disabilities

Summary: the main aim of the study is to investigate whether intranasal oxytocin (24iu) influences reward sensitivity and performance monitoring during reinforcement learning.

a double-blind, within-subject, placebo-controlled pharmacological eeg design will be employed. a total of 35 healthy male subjects will be recruited which will receive either intranasal placebo or oxytocin (24iu) on two separate study days (order counter-balanced, washout period at least 2 weeks). 45 minutes after treatment subjects will undergo a probabilistic feedback reinforcement learning paradigm with concurrent eeg acquisition. during the paradigm subjects will learn the reward probabilities of two different visual stimuli from probabilistic feedback provided by social stimuli (positive, negative emoticon). the paradigm includes an initial acquisition phase and a subsequent test phase.

Eligibility criteria:
inclusion criteria: * age between 18-30 * male sex * right handedness exclusion criteria: * history of brain injury * current or history of psychiatric, neurological or internist disorder * current or regular use of medication, psychotropic substances, including nicotine * contraindications for oxytocin

Keywords: oxytocin performance monitoring reinforcement learning
batch enrollment for ai-guided intervention to lower neurologic events in unrecognized af

Conditions: Atrial Fibrillation

Summary: this is a prospective study to test a novel artificial intelligence (ai)-enabled electrocardiogram (ecg)-based screening tool for improving the diagnosis of unrecognized atrial fibrillation (af) and stroke prevention.


Eligibility criteria:
inclusion criteria: * age ≥18 years * had a 10-second 12-lead ecg done at mayo clinic * men with cha2ds2-vasc ≥2 or women with cha2ds2-vasc ≥3 exclusion criteria: * diagnosed atrial fibrillation or atrial flutter * missing date of birth or sex in the electronic health record (ehr) * a history of intracranial bleeding * a history of end-stage kidney disease * have an implantable cardiac monitoring device, including a pacemaker, a defibrillator, or implanted loop recorder * deemed by research personnel to have limitations that would prevent them from being able to provide informed consent, use the patch, or complete interviews will not be included.
comparisons of the therapeutic effects of dienogest and danazol on endometriosis

Conditions: Endometriosis

Summary: the aim of this study is to evaluate the efficacy between dienogest and danazol.

objective: women with adenomyosis or endometripsis are often suffered from dysmenorrhea or menorrhagia. dienogest and danazol are frequently used for the treatment of endometriosis. however, there was no literature mentioned about which medication is better for the treatment of endometriosis. thus, the aim of this study is to evaluate the efficacy between dienogest and danazol. methods: all consecutive women, who have endometriosis, will be randomized to receive dienogest or danazol treatment, and will assess symptoms severity, receive ca125 examination, sonographic examination at baseline, 4 weeks and 16 weeks after treatment.

Eligibility criteria:
inclusion criteria: * \> 20 years old * have an endometriosis-related condition (including adenomyosis, adenomyoma, ovarian endometrioma, or pelvic endometriosis). exclusion criteria: * minors. * have a history of breast cancer or other cancers. * patients with vascular obstruction such as stroke.